Figure 4.
Adaptive Factors Have Minimal Contributions to the CNS Protection Induced by VSVΔ51 Priming
Top: nude mice were primed i.p. with 2 × 108 PFU VSVΔ51-GFP or PBS for 48 hr, followed by IC treatment with 1 × 107 PFU VSVΔ51-fLuc, based on 3 mice per group. (A and B) IVIS imaging was used to measure luciferase signal and track IC-administered virus: (A) luminesce images; (B) graph of total flux. Dotted line indicates background luminescence. Error bars refer to SD. (C) Survival curves were assessed by log-rank (Mantel-Cox) test. *p < 0.05. (D) Bottom: luminescence from IC-applied virus was analyzed in primed u-chain-deficient mice, based on 3 mice per group. Error bars refer to SD. (E) Detection of anti-VSV neutralizing antibodies in the serum of BALB/c mice primed with 1 × 108 PFU VSVΔ51-GFP or PBS and analyzed at 24 or 48 hr post-prime by plaque reduction assay on Vero cells based on 3 mice per group. Dotted line represents limit of detection. Statistics were calculated by one-way ANOVA analysis. ns, not significant; ***p < 0.001. Negative control represents media alone. Positive control represents serum isolated from VSV immune mice (primed with 1 × 108 PFU VSVΔ51-GFP for 144 hr).